| Company Name: |
Bide Pharmatech Ltd.
|
| Tel: |
400-1647117 13681763483 |
| Email: |
product02@bidepharm.com |
| Products Intro: |
Product Name:4-Amino-N-((S)-1-(4-chlorophenyl)-3-(4-(11-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-11-oxoundecanoyl)piperazin-1-yl)propyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
CAS:2376137-05-0
Purity:95% Package:1mg;5mg;10mg;25mg Remarks:BD01474841
|
| Company Name: |
Nantong QuanYi Biotechnology Co., Ltd
|
| Tel: |
0513-66337626 18051384581 |
| Email: |
sales@chemhifuture.com |
| Products Intro: |
Product Name:MS21
CAS:2376137-05-0
Purity:98%+HPLC Package:10mg，100mg，500mg，1g，2g，5g，10g，More
|
|
| Product Name: | MS21 | | Synonyms: | MS21;4-amino-N-[(1S)-1-(4-chlorophenyl)-3-[4-(10-{[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}decanoyl)piperazin-1-yl]propyl]-1-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}piperidine-4-carboxamide;4-Amino-N-((S)-1-(4-chlorophenyl)-3-(4-(11-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-11-oxoundecanoyl)piperazin-1-yl)propyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide | | CAS: | 2376137-05-0 | | MF: | C58H79ClN12O6S | | MW: | 1107.85 | | EINECS: | | | Product Categories: | | | Mol File: | 2376137-05-0.mol |  |
| density | 1.267±0.06 g/cm3(Predicted) | | pka | 13.93±0.50(Predicted) | | form | Solid | | color | White to off-white |
| Uses | MS21 is an effective AKT PROTAC degrader. MS21 can inhibit mutations in the PI3K/PTEN pathway, suppress the proliferation and induce cell cycle arrest of tumor cells. MS21 has anti-tumor activity. (Pink: AKT ligand-2 (HY-48682); Black: Linker (HY-W014125); Blue: (S,R,S)-AHPC (HY-125845))[1]. | | in vivo | MS21 (75 mg/kg; intraperitoneal injection; 21 days) exhibits anti-tumor activity in nude mouse models bearing PC-3/MDA-MB-468 xenografts, and can reduce the level of T-AKT protein in tumor tissues and shows good tolerance[1]. | | References | [1] Xu J, et al. AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway-Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B. Cancer Discov. 2021 Jul 23. DOI:10.1158/2159-8290.CD-20-0815 |
| | MS21 Preparation Products And Raw materials |
|